About Vyriad
Vyriad is a company based in Rochester (United States) founded in 2016. It operates as a HealthTech. Vyriad has raised $87.88 million across 8 funding rounds from investors including Regeneron Pharmaceuticals, Mirae Asset and Mayo Clinic. Vyriad offers products and services including Oncolytic Virus Platforms and In Vivo Gene Therapies. Vyriad operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Rochester, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$87.88 M (USD)
in 8 rounds
-
Latest Funding Round
$25 M (USD), Series B
Dec 24, 2025
-
Investors
Regeneron Pharmaceuticals
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vyriad
Vyriad offers a comprehensive portfolio of products and services, including Oncolytic Virus Platforms and In Vivo Gene Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targeted therapies are developed using oncolytic virus platforms.
Gene therapies are engineered for in vivo delivery solutions.
Unlock access to complete
Unlock access to complete
Funding Insights of Vyriad
Vyriad has successfully raised a total of $87.88M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $25.0M
-
First Round
First Round
(01 Mar 2018)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Series B - Vyriad | Valuation | Harry Stine |
|
| May, 2022 | Amount | Series B - Vyriad | Valuation | Harry Stine | |
| Nov, 2019 | Amount | Series A - Vyriad | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vyriad
Vyriad has secured backing from 9 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Regeneron Pharmaceuticals, Mirae Asset and Mayo Clinic. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mirae Asset is engaged in mutual fund and asset management services.
|
Founded Year | Domain | Location | |
|
Early-stage investment capital is provided to Minnesota entrepreneurs.
|
Founded Year | Domain | Location | |
|
General medical clinics are operated throughout the United States.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vyriad
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vyriad
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vyriad Comparisons
Competitors of Vyriad
Vyriad operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vyriad
Frequently Asked Questions about Vyriad
When was Vyriad founded?
Vyriad was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Vyriad located?
Vyriad is headquartered in Rochester, United States.
Is Vyriad a funded company?
Vyriad is a funded company, having raised a total of $87.88M across 8 funding rounds to date. The company's 1st funding round was a Series A of $24.38M, raised on Mar 01, 2018.
What does Vyriad do?
Vyriad is engaged in the development of targeted genetic therapies, including in vivo gene therapies, genome editing, and oncolytic virotherapies. The company is based in Rochester, Minnesota, and collaborates with leading medical institutions and pharmaceutical companies. Solutions are built on stable virus platforms such as vesicular stomatitis virus (VSV) and measles-based oncolytic viruses. Clinical trials are conducted for multiple cancer indications in partnership with entities like Regeneron and Mayo Clinic. A cross-functional approach is adopted, integrating preclinical development, manufacturing, and clinical expertise to deliver tailored viral delivery solutions.
Who are the top competitors of Vyriad?
Vyriad's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Vyriad offer?
Vyriad offers Oncolytic Virus Platforms and In Vivo Gene Therapies.
Who are Vyriad's investors?
Vyriad has 9 investors. Key investors include Regeneron Pharmaceuticals, Mirae Asset, Mayo Clinic, HHS, and Minnesota.gov.